Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOAC-1101: UFT/LV vs TEGAFOX as adjuvant therapy in high-risk stage II/III colorectal cancer
jRCTs031180381Phase 2Completed
- Start
- Jun 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tegafur + uracil, folinic acid and oxaliplatin in colorectal cancer (CRC) (2 arms). Primary endpoint: 3-year disease-free survival rate. Started Jun 2011; status: completed.
02
Drugs
tegafur + uracilfolinic acidoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180381.